Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver.

Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3126-31. Unique Identifier : AIDSLINE MED/96181547
Kollmann TR; Pettoello-Mantovani M; Katopodis NF; Hachamovitch M; Rubinstein A; Kim A; Goldstein H; Department of Microbiology and Immunology, Albert Einstein; College of Medicine, Bronx NY 10461, USA.

Abstract: To improve the usefulness of in vivo mode for the investigation of the pathophysiology of human immunodeficiency virus (HIV) infection, we modified the construction of SCID mice implanted with human fetal thymus and liver (thy/liv-SCID-hu mice) so that the peripheral blood of the mice contained significant numbers of human monocytes and T cells. After inoculation with HIV-1(59), a primary patient isolate capable of infecting monocytes and T cells, the modified thy/liv-SCID-hu mice developed disseminated HIV infection that was associated with plasma viremia. The development of plasma viremia and HIV infection in thy/liv-SCID-hu mice inoculated with HIV-1(59) was inhibited by acute treatment with human interleukin (IL) 10 but not with human IL-12. The human peripheral blood mononuclear cells in these modified thy/liv-SCID-hu mice were responsive to in vivo treatment with exogenous cytokines. Human interferon gamma expression in the circulating human peripheral blood mononuclear cells was induced by treatment with IL-12 and inhibited by treatment with IL-10. Thus, these modified thy/liv-SCID-hu mice should prove to be a valuable in vivo model for examining the role of immunomodulatory therapy in modifying HIV infection. Furthermore, our demonstration of the vivo inhibitory effect of IL-10 on acute HIV infection suggests that further studies may be warranted to evaluate whether there is a role for IL-10 therapy in preventing HIV infection in individuals soon after exposure to HIV such as for children born to HIV-infected mothers.

Keywords: Animal Antigens, CD/ANALYSIS Cytokines/*BIOSYNTHESIS Fetal Tissue Transplantation/IMMUNOLOGY Flow Cytometry Gene Expression Human HIV Infections/*IMMUNOLOGY/*PREVENTION & CONTROL/THERAPY *HIV-1/PHYSIOLOGY Interferon Type II/BIOSYNTHESIS Interleukin-10/*THERAPEUTIC USE Liver Transplantation/*IMMUNOLOGY Mice Mice, SCID Monocytes/IMMUNOLOGY Polymerase Chain Reaction RNA, Viral/BLOOD Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes/*IMMUNOLOGY Thymus Gland/*IMMUNOLOGY/*TRANSPLANTATION Transplantation, Heterologous/IMMUNOLOGY Virus Replication JOURNAL ARTICLE
960830
M9681144

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .